Astrazeneca (AZN) Stock
Global pharmaceutical company with strong cancer and respiratory portfolio. Here's the price, business snapshot, and what's worth knowing about Astrazeneca in September 2026.
AstraZeneca PLC (AZN) is a large‑cap global biopharmaceutical company focused on discovery, development and commercialisation of prescription medicines, with particular strength in oncology, cardiovascular, renal & metabolic (CVRM), and respiratory therapies. The firm combines a broad marketed portfolio with an active R&D pipeline and significant investment in biologics and precision medicines. For investors, key considerations include steady revenue from established drugs, growth driven by newer oncology and rare‑disease launches, and continued R&D spend that can both support long‑term value and create near‑term earnings variability. The company operates globally, exposing it to different regulatory and pricing environments and currency movements. AstraZeneca has historically paid dividends, but dividend levels and share price can fluctuate with trial outcomes, patent expiries and competition. This summary is educational only — not personalised investment advice — and investors should weigh growth potential against clinical, regulatory and commercial risks.
Why It’s Moving
AstraZeneca catches a bid as fresh financing and steady earnings guidance keep growth momentum in focus
- AstraZeneca priced a €2.55 billion Eurobond, signaling it is locking in long-term funding at fixed rates while investor attention stays on its capital strategy.
- The company’s H1 and Q2 2026 results continue to anchor sentiment, with management guiding for mid-to-high single-digit revenue growth and low double-digit core EPS growth in 2026, reinforcing the growth narrative behind the shares.
- Analyst expectations for the next report remain constructive, with consensus pointing to another year-over-year earnings increase, which is helping support the case for upside as the market waits for the next catalyst.
AstraZeneca catches a bid as fresh financing and steady earnings guidance keep growth momentum in focus
- AstraZeneca priced a €2.55 billion Eurobond, signaling it is locking in long-term funding at fixed rates while investor attention stays on its capital strategy.
- The company’s H1 and Q2 2026 results continue to anchor sentiment, with management guiding for mid-to-high single-digit revenue growth and low double-digit core EPS growth in 2026, reinforcing the growth narrative behind the shares.
- Analyst expectations for the next report remain constructive, with consensus pointing to another year-over-year earnings increase, which is helping support the case for upside as the market waits for the next catalyst.
Sixth Month Growth Performance
When is the next earnings date for ASTRAZENECA PLC (AZN)?
AstraZeneca’s next earnings date is expected on October 30, 2026, based on its established reporting pattern. The report will cover Q3 2026 and likely the first nine months of 2026. The company has also indicated that its 9M and Q3 2026 results are scheduled for that date.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying AstraZeneca's stock with a target price of $114.08, indicating potential growth.
Financial Health
AstraZeneca is generating strong revenue and profits, supported by healthy cash flow metrics.
Dividend
AstraZeneca's average dividend yield of 3.14% makes it a reasonable choice for those seeking dividend income. If you invested $1000 you would be paid $31.40 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Pipeline drives growth
AstraZeneca’s R&D pipeline, especially in oncology and precision medicines, can support future revenue, though trial outcomes and approvals are uncertain.
Global footprint matters
Wide geographic reach diversifies revenue but brings exposure to regulatory, pricing and currency risks that can affect results.
Innovation and spending
Heavy investment in biologics and new modalities underpins long‑term potential while creating earnings variability in the near term.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
